Study Comparing IV Clevidipine With Other IV Antihypertensive Treatments in Adults With Acute Intracerebral Hemorrhage and High Blood Pressure
Led by Zeenat Qureshi Stroke Institute · Updated on 2026-10-30
1018
Participants Needed
21
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are comparing how quickly people with high blood pressure and intracerebral hemorrhage ICH can reach a stable target systolic blood pressure SBP within 60 minutes using two different intravenous treatments. The study focuses on patients with acute stroke symptoms and elevated SBP between 150 and 220 mmHg, aiming to evaluate the effectiveness of clevidipine versus other standard IV antihypertensive regimens. This research is sponsored by the Zeenat Qureshi Stroke Institute and involves adults aged 18 to 100 years.
Participants receive either IV clevidipine or an alternate IV antihypertensive medication depending on the hospital type. Clevidipine dosing starts at 1-2 mghour and is adjusted frequently to reach the blood pressure goal, with dose increases slowing as the target is approached. Doses typically range from 4-6 mghour, with a maximum infusion volume limit to avoid lipid overload. The alternate regimen often involves IV nicardipine, starting at 5 mghour and adjusted as needed per FDA guidelines. Treatment initiation occurs within 12 hours of neurological symptom onset.
During the study, participants undergo blood pressure monitoring every 15 minutes to assess stability and response to treatment. Eligibility includes clinical stroke signs and confirmed brain hematoma on CT scan, with follow-up visits planned at 90 and 180 days after enrollment. Informed consent is required, and patients undergoing surgical or drainage interventions under guideline timing are included unless surgery is performed within 6 hours of treatment start. Safety and treatment effects are carefully tracked throughout the study period ending in 2028.
CONDITIONS
Brief Title
Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
New neurological deficits within 12 hours before enrollment
Clinical signs of stroke such as language, motor, cognitive, or vision impairment
NIH Stroke Scale score of 1 or greater
Glasgow Coma Scale score of 5 or greater at enrollment
Brain CT scan showing intraparenchymal hematoma volume greater than 5 cc
Admission systolic blood pressure between 150 and 220 mmHg on two measurements 5 to 10 minutes apart
Signed informed consent before hospital discharge
Patients with anticoagulant-related ICH with concurrent reversal treatment
Patients undergoing surgical evacuation unless surgery is within 6 hours of treatment start
Patients requiring external ventricular drainage per guidelines
You will not qualify if you...
Symptom onset time cannot be reliably determined
Known brain tumors, arteriovenous malformations, or aneurysms
Hematoma caused by trauma
ICH located in infratentorial regions such as pons or midbrain
Candidates for immediate neurosurgical intervention
Pregnancy, recent childbirth within 30 days, or active breastfeeding
History of bleeding disorders except anticoagulant-related ICH
Platelet count below 50,000/mm3
Known allergy to nicardipine or clevidipine
Living will limiting aggressive ICU care
Allergies to soy, soy products, eggs, or egg products
Disorders of lipid metabolism with hyperlipidemia
Severe aortic stenosis
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Up to 12 hours from symptom onset
Participants receive intravenous clevidipine or an alternate antihypertensive drug to control blood pressure following acute intracerebral hemorrhage.
Follow-up
Duration - 6 months
Participants have follow-up visits at 90 and 180 days after enrollment to assess health outcomes and treatment effects.
2 visits
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Study Evaluating Combined Cognitive and Balance Rehabilitation for Adults Recovering From Stroke
AI-Assisted Smart Family Doctor for Managing Hypertension, Diabetes, and Dyslipidemia in Adults After Coronary Artery Bypass Graft or Percutaneous Coronary Intervention
PILI 0ina Project to Improve Diet and Health in Native Hawaiian Adults with Cardiometabolic Conditions Through Community Cooking Demonstrations
Study of the Eat Well Produce Prescription Program for Veterans with Hypertension, Diabetes, or Obesity at Risk of Food Insecurity
Using 5T MRI and Metabolomics to Predict Hemorrhage Risk in Moyamoya Disease A Prospective Observational Cohort Study
Study of Vascular Function and Exercise Effects in Aging and Cardiovascular Diseases Including COPD and Pulmonary Hypertension
Testing Caregiver-Assisted Strategy Training to Improve Daily Activities for Adults After Stroke in a Multi-Center Trial
Stroke Recovery Study Using EEG-Guided Muscle and Tongue Stimulation
Evaluating Brain-Computer Interface and Functional Electric Stimulation Therapy
Community Cluster-Randomized Trial Evaluating a Hypertension Risk Model-Based Precision Intervention for Adults at High Risk in Shunyi District, Beijing
Observational Cohort Study of Biomarkers and Health Outcomes in Adults with Hypertension in Guangdong Province
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
The Association between Hourly Systolic Blood Pressure Variability and Outcomes in Patients with Intracerebral Hemorrhage is Time-Dependent: Post-hoc Analysis of the ATACH-2 Trial.